Dermatomyositis

For patient information click here

Dermatomyositis
X-Ray of the knee in a patient with dermatomyositis.
ICD-10	M33.0-M33.1
ICD-9	710.3
DiseasesDB	10343
MedlinePlus	000839
MeSH	D003882

Dermatomyositis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Dermatomyositis from other Diseases
Epidemiology and Demographics
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
MRI
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Dermatomyositis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Dermatomyositis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Dermatomyositis
CDC on Dermatomyositis
Dermatomyositis in the news
Blogs on Dermatomyositis
Directions to Hospitals Treating Dermatomyositis
Risk calculators and risk factors for Dermatomyositis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Dermatomyositis is connective-tissue disease that is characterized by inflammation of the muscles and the skin. Its cause is unknown, but it may result from either a viral infection or an autoimmune reaction. Up to 50% of the cases may be a paraneoplastic phenomenon, indicating the presence of cancer.

X-ray findings include dystrophic calcifications in the muscles.

There is a form of this disorder that strikes children, known as juvenile dermatomyositis.

"Gottron's papules", pink patches on the knuckles, and priapism, are associated with this disorder.

Differential Diagnosis

Dermatomyositis must be differentiated from other common, lymphocyte predominant inflammatory myopathies. If present, the characteristic perifascicular atrophy makes this distinction trivial.

There is some overlap in the microscopic appearances of different inflammatory myopathies, but some helpful differences are often present. The rimmed vacuoles of inclusion body myositis (IBM) are absent in dermatomyositis. Polymyositis is characterised by diffuse or patchy inflammation of the muscle fascicles, a random pattern of muscle atrophy, and T-cell predominance with T-cells seen invading otherwise viable appearing muscle fibers.

Pathology

The diagnosis of dermatomyositis can be confirmed by muscle biopsy, EMG,and blood tests. It should be noted, however, that only muscle biopsy is truly diagnostic (pathognomic); liver enzymes and EMG are relatively non-specific. Liver enzymes, specificly creatine phosphokinase (CPK), are the major tool in assessing the progress of the disease and/or the efficacy of treatment. On the muscle biopsy, there are two classic microscopic findings of dermatomyositis. They are:

• A mixed B- and T-cell perivascular inflammatory infiltrate
• Perifascicular muscle fiber atrophy

Dermatomyositis is associated with autoantibodies, especially anti-Jo1 antibody.

Mechanism

The mechanism is conjectured to be complement-mediated damage of microscopic vessels with muscle atrophy and lymphocytic inflammation secondary to tissue ischemia.

Classification

Dermatomyositis may be a type of autoimmune connective tissue disease. It is related to polymyositis and inclusion body myositis.

There is a form of this disorder that strikes children, known as juvenile dermatomyositis(JDM). For the most part Juvenile dermatomyositis is the same as the adult form, but the relationship with cancer is far lower, or non-existent.

Causes

The cause is unknown, but it may result from either a viral infection or an autoimmune reaction. Some cases of dermatomyositis actually "overlap" (are combined with) another autoimmune disease such as lupus, scleroderma, or vasculitis. Because of the link between DM and autoimmune disease, doctors and patients suspecting DM may find it helpful to run an ANA - antinuclear antibody - test, which in cases of a lupus-like nature may be positive (usually from 1:160 to 1:640, with normal ranges at 1:40 and below).

Some cases of DM are a paraneoplastic phenomenon, indicating the presence of cancer. In cases involving cancer, the cancer is usually pre-existent, with removal of the cancer resulting in remission of the DM. The onset of a rash in patients with pre-existing myositis requires investigation of the neoplastic possibility.

In 1988, the noted Lyme disease researcher Dr. Alan Steere observed: "Finally, the perivascular lymphoid infiltrate in clinical myositis does not differ from that seen in polymyositis or dermatomyositis. All of these histologic derangements suggest immunologic damage in response to persistence of the spirochete, however few in number.", in his article, Clinical pathologic correlations of Lyme disease by stage.

Microscopic findings

Cross sections of muscle reveal muscle fascicles with small, shrunken polygonal muscle fibers on the periphery of a fascicle surrounding central muscle fibers of normal, uniform size.

Aggregates of mature lymphocytes with small, dark nuclei and scant cytoplasm are seen surrounding vessels. Other inflammatory cells are distinctly uncommon. Immunohistochemistry can be used to demonstrate that both B- and T-cells are present in approximately equal numbers.

Mechanism

The mechanism is conjectured to be complement-mediated damage of microscopic vessels with muscle atrophy and lymphocytic inflammation secondary to tissue ischemia .

Presentation

X-ray findings sometimes include dystrophic calcifications in the muscles, and patients may or may not notice small calcium deposits under the skin. Many do not have any calcium deposits of any kind. The rash also may come and go, and may not be dependent on the severity of the muscle involvement at the time. "Gottron's papules", pink patches on the knuckles, and priapism, are associated with this disorder.

Diagnosis

History and Symptoms

The main symptoms include skin rash and symmetric proximal muscle weakness which may be accompanied by pain. The pain may resemble the type experienced after strenuous exercise. Some DM patients have little pain, while in others (esp. in JDM), the pain may be severe. It is important to remember that this condition varies from person to person in many ways.

Skin findings occur in DM but not PM and are generally present at diagnosis. Gottron's sign is an erythematous, scaly eruption occurring in symmetric fashion over the MCP and interphalangeal joints (can mimic psoriasis). Heliotrope rash (or lilac rash) is a violaceous eruption on the upper eyelids, often with swelling (most specific, though uncommon). Shawl (or V-) sign is a diffuse, flat, erythematous lesion over the chest and shoulders or in a "V" over the anterior neck and chest, worsened with UV light. Erythroderma is a flat, erythematous lesion similar to the shawl sign but located in other areas, such as the malar region and the forehead. Periungual telangiectasias and erythema occur.

Mechanic's hands (also in PM) refers to rough, cracked skin at the tips and lateral aspects of the fingers forming irregular dirty-appearing lines that resemble those seen in a laborer (this is also associated with the anti-synthetase syndrome).See: sclerodactyly. Psoriaform changes in the scalp can occur. Centripetal flagellate erythema comprises linear, violaceous streaks on the trunk (possibly caused by itching pruritic skin). Calcinosis cutis (deposition of calcium in the skin) is usually seen in juvenile DM, not adult DM. Dysphagia (difficulty swallowing) is another feature, occurring in as much as 33% of cases.

Physical Examination

Heliotrope rash (Dermatomyositis) Prox muscle weakness

Diagnostic Findings

Patient #1

Images courtesy of RadsWiki

• 
• 

• 
• 

Patient #2

Images courtesy of RadsWiki

• 
• 

Treatment

There is no cure for dermatomyositis, but the symptoms can be treated. Options include medication, physical therapy, exercise, heat therapy (including microwave and ultrasound), orthotics and assistive devices, and rest. The standard treatment for dermatomyositis is a corticosteroid drug, given either in pill form or intravenously.

Immunosuppressant drugs, such as azathioprine and methotrexate, may reduce inflammation in people who do not respond well to prednisone.

Periodic treatment using intravenous immunoglobulin can also improve recovery. Other immunosuppressive agents used to treat the inflammation associated with dermatomyositis include cyclosporine A, cyclophosphamide, and tacrolimus.

Physical therapy is usually recommended to prevent muscle atrophy and to regain muscle strength and range of motion. Many individuals with dermatomyositis may need a topical ointment, such as topical corticosteroids, for their skin disorder. They should wear a high-protection sunscreen and protective clothing. Surgery may be required to remove calcium deposits that cause nerve pain and recurrent infections.

1. Prednisolone
2. Methotrexate
3. Mycophenolate (CellCept / Myfortic)
4. Intravenous immunoglobulin
5. Azathioprine
6. Cyclophosphamide
7. Rituximab

Prognosis

Most cases of dermatomyositis respond to therapy. The disease is usually more severe and resistant to therapy in individuals with cardiac or pulmonary problems.

External links

• Dermatomyositis at Medline-Plus
• Goldminer: Dermatomyositis
• The American College of Rheumatology's patient education page on myopathy
• Illustration of Gottron's papules
• Polymyositis and Dermatomyositis Discussion group
• The Myositis Association

Template:Muscular Dystrophy Template:Diseases of the musculoskeletal system and connective tissue

de:Dermatomyositis nl:Dermatomyositis

Template:WikiDoc Sources